Nabla Bio Closes $11M Seed Financing Led By Khosla Ventures And Zetta Venture Partners

Dec 06, 2021•about 4 years ago

Amount Raised

$11 Million

Round Type

seed

Boston

Description

Nabla Bio, a next-generation antibody design company, announced the closing of a $11M Seed financing round. The round was co-led by Khosla Ventures and Zetta Venture Partners, with participation from Fifty Years, Cantos Ventures, and others.

Company Information

Company

Nabla Bio

Location

Boston, Massachusetts, United States

About

Nabla Bio is an antibody design company. The company’s AI-first protein design platform enables rapid engineering of best-in-class antibody therapeutics. The foundational technology was developed by CEO Surge Biswas, academic Co-Founder George Church and their team at Harvard, and has advanced the field of machine learning-guided protein modeling and design. The company has a fully functional wet lab to complement its machine learning capabilities. Nabla Bio is based in Boston, MA. For additional information, please visit www.nabla.bio.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Nabla Bio Closes $11M Seed Financing Led By Khosla Ventures And Zetta Venture Partners

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information